scispace - formally typeset
S

Sohei Yamamoto

Researcher at National Defense Medical College

Publications -  33
Citations -  1515

Sohei Yamamoto is an academic researcher from National Defense Medical College. The author has contributed to research in topics: Adenocarcinoma & Ovarian Clear Cell Adenocarcinoma. The author has an hindex of 18, co-authored 33 publications receiving 1375 citations.

Papers
More filters
Journal ArticleDOI

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

TL;DR: The degree of TIL correlated with immune response appear to play a substantial role in the response to NAC in TNBC, and Expression of basal markers and p53, histological grade 3, high TIL scores, and apoptosis were more frequent in T NBC and the HR−/her2+ subtype than in the HR+/HER2− subtype.
Journal ArticleDOI

Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.

TL;DR: The results suggest that loss of ARID1A protein expression occurs as a very early event in ovarian clear-cell carcinoma development, similar to the pattern of PIK3CA mutation recently reported by the group, and frequently coexists (not mutually exclusive) with Pik3CA mutations.
Journal ArticleDOI

PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.

TL;DR: Findings provide evidence that mutations of the PIK3CA gene occur in the putative precursor lesions of CCA, strongly suggesting that they are very early events in tumourigenesis, probably initiating the malignant transformation of endometriosis.
Journal ArticleDOI

Immunohistochemical detection of hepatocyte nuclear factor 1β in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium☆

TL;DR: HNF-1beta would be an excellent marker for distinguishing CCAs from other lesions in both the ovary and the endometrium and seems to be associated with physiopathological cytoplasmic glycogen accumulation in these organs.
Journal ArticleDOI

Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance

TL;DR: The actinin-4 gene may be a target of the 19q amplicon, acting as a candidate oncogene, and serve as a predictor of poor outcome and tumor chemoresistance in patients with advanced-stage ovarian cancers.